EUS-guided core biopsies of pancreatic solid masses using a new fork-tip needle: A multicenter prospective study. Issue 9 (September 2019)

• Record Type: Journal Article
• Authors: Di Leo, Milena; Crinò, Stefano Francesco; Bernardoni, Laura; Rahal, Daoud; Auriemma, Francesco; Correale, Loredana; Donato, Giulio; Massidda, Marco; Anderloni, Andrea; Manfrin, Erminia; Armellini, Elia; Poliani, Laura; Fugazza, Alessandro; Semeraro, Rossella; Occhipinti, Pietro; Repici, Alessandro; Carrara, Silvia
• Is Part Of: Digestive and liver disease. Volume 51:Issue 9(2019)
• Page Start: 1275
• Page End: 1280
• Publication Date: 2019-09
• Subjects: FNA -- FNB -- Pancreatic adenocarcinoma -- SharkCore needle -- Tissue acquisition; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2019.03.025
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background and aim: Endoscopic ultrasound-guided sampling (EUS sampling) is a safe and effective technique. The study aim was to evaluate the presence of a histological core from pancreatic lesions using a new 25G fork-tip needle. Methods: Observational multicenter prospective and analytical study, including consecutive patients with solid pancreatic masses referred for EUS-guided sampling. At each needle pass, the endoscopist performed macroscopic on-site evaluation (MOSE). The primary outcome was the histological core procurement rates. Secondary outcomes were the evaluation of interobserver agreement between endoscopists and pathologists, adequacy of EUS samples for the diagnosis and post-procedure adverse events. Results: 100 patients were enrolled in 3 centers. The mean size of the lesions was 28.5 mm (SD 11.7). Final diagnoses were adenocarcinoma (68%), neuroendocrine tumor (21%), inflammatory mass/benign lesions (8.0%), and pancreatic metastasis (3.0%). The pathologists described the presence of a core in 67 samples (67.0% of patients), with poor agreement with MOSE (kappa, 0. 12; 95% CI: 0.03–0.28). The diagnostic accuracy was 93%. We observed 6% of mild adverse events. Conclusion: The new 25-gauge core needle showed good overall adequacy and a good rate of histological specimens during EUS sampling of solid pancreatic masses, with a minimum number of passes and no major complications. Clinicaltrial.gov number, NCT02946840.